• Dementia affects millions of people worldwide, and numbers are increasing rapidly.
• One factor that may increase the risk of dementia is high levels of blood cholesterol.
• Now, a study has found that low levels of LDL-C, or ‘bad’ cholesterol, may reduce the risk of developing dementia.
• Statins, a cholesterol-lowering medication, could reduce the risk of dementia further in people with low LDL-C.

A new study reveals that while low-carb, high-fat diets may spare saturated fats and carbs from blame, high cholesterol and salt intake still threaten heart health—urging smarter food choices even in trendy diets.

A “weekend warrior” approach to physical activity — getting 150 minutes of moderate-to-vigorous physical activity over one to two days instead of throughout the week — improved health and lowered the risk of death, finds a new study in the Journal of the American Heart Association

For patients who have undergone a procedure to unclog the arteries, clopidogrel (the generic of Plavix) was better able to reduce the risk of future cardiac events than aspirin. After a median follow-up of over two years, patients taking clopidogrel were 29% less likely than those taking aspirin to experience all-cause death, heart attack or stroke, according to findings of a new study that was presented at the American College of Cardiology Annual Scientific Session and Expo and published simultaneously in The Lancet.

High LP(a) levels and the presence of CAC are independently associated with ASCVD. Given that both markers were additively associated with ASCVD when elevated, more aggressive management to reduce cardiovascular risk may be warranted. However, high LP(a)/CACS = 0 did not significantly increase the OR for ASCVD (1.36 [0.90, 2.05]).

Elevated Lp(a) levels were not associated with new-onset CAC or progression of existing CAC in this large longitudinal cohort.

Lepodisiran reduced mean serum concentrations of lipoprotein(a) from 60 to 180 days after administration.

In a new paper published in the journal Magnetic Resonance Imaging, a team led by Brent Wagner, MD, professor in the Department of Internal Medicine in the UNM School of Medicine, sought to explain the formation of the nanoparticles, which have been associated with serious health problems in the kidneys and other organs.